Media

For media enquiries please contact:
media@evivebiotech.com

Latest Press Release

Evive Biotech Meets Primary and Secondary Endpoints in Global Phase III Clinical Trial for Their Novel Chemotherapy-induced Neutropenia Treatment

Evive Successfully Concludes China Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia

Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease

Evive Announces Initiation of a Phase I Trial of A-319 to Treat Patients with B Cell Malignancies

Evive Receives Investigative New Drug (IND) Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies

Evive’s F-652 Shows Positive Results in “An Open Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy in Patients with Alcoholic Hepatitis”

Evive Successfully Concludes First Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia and met primary endpoints

China Patent Office Grants a Bi-Specific Antibody Patent to Evive

Evive Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in Chemotherapy-induced Neutropenia

Media Library